We have taken over 70 companies to a successful exit since setting up the Novartis Venture Fund in 1996 – that is three on average per year. These exits have primarily resulted in IPOs and M&As, with several drugs receiving FDA approval. Nearly 40 companies completed initial public offerings (IPO) Over 30 progressed to a merger and acquisition by a number of top pharmaceutical companies.